Irinotecan and Its Active Metabolite SN-38: Understanding Their Effects
Author Information
Author(s): Mathijssen R H J, Verweij J, Loos W J, de Bruijn P, Nooter K, Sparreboom A
Primary Institution: Erasmus MC–Daniel den Hoed
Hypothesis
Does prolonged exposure to SN-38, the active metabolite of irinotecan, have clinical relevance toward toxicity?
Conclusion
Prolonged exposure to low concentrations of SN-38 has significant cytotoxic potential and clinical implications for toxicity and antitumor activity.
Supporting Evidence
- SN-38 concentrations in plasma can induce significant cytotoxicity in vitro.
- A new limited-sampling model for SN-38 AUC500 h was developed.
- Prolonged exposure to SN-38 correlates with decreased absolute neutrophil count.
- Patients with prolonged neutropenia have a greater risk of infection.
- Using the entire time course of neutrophil counts provides better predictive power for toxicity.
Takeaway
This study shows that a medicine called irinotecan can stay in the body for a long time, and its effects can be strong even at low amounts.
Methodology
The study involved in vitro analysis of SN-38 cytotoxicity and pharmacokinetic data from 26 cancer patients treated with irinotecan.
Potential Biases
Potential bias due to the retrospective nature of patient data collection.
Limitations
The study had a small sample size and excluded patients with extreme pre-treatment haematological values.
Participant Demographics
Patients predominantly suffering from colorectal cancer, aged between 18 and 70 years.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website